C

The proof-of-concept trial found some significant improvements in oxygen desaturation time and certain apnea-related indices with fenofibrate, but no change in the primary AHI outcome; the authors conclude that these exploratory findings “may support further investigation” rather than establishing a definitive therapeutic role [Bruckert, 2010, PMID: 20297950].